Items where authors include "Barrett-Lee, P."

Article

Velikova, G. orcid.org/0000-0003-1899-5942, Morden, J.P., Haviland, J.S. et al. (14 more authors) (2023) Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial. The Lancet Oncology. ISSN 1470-2045

Coleman, R.E., Collinson, M., Gregory, W. et al. (20 more authors) (2018) Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04). JOURNAL OF BONE ONCOLOGY, 13. pp. 123-135. ISSN 2212-1374

Tutt, A., Tovey, H., Cheang, M.C.U. et al. (35 more authors) (2018) Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nature Medicine, 24 (5). pp. 628-637. ISSN 1078-8956

Cameron, D., Morden, J.P., Canney, P. et al. (21 more authors) (2017) Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. The Lancet Oncology, 18 (7). pp. 929-945. ISSN 1470-2045